Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

被引：0

作者：

Ledermann, J. A. ^{[1
]}

Perren, T. J. ^{[2
]}

Raja, F. A. ^{[1
]}

Embleton, A. ^{[3
]}

Rustin, G. J. S. ^{[4
]}

Jayson, G. ^{[5
]}

Kaye, S. B. ^{[6
]}

Swart, A. M. ^{[3
]}

Vaughan, M. ^{[7
]}

Hirte, H. ^{[8
]}

机构：

[1] UCL Canc Inst, Canc Res UK & UCL Trials Ctr, London, England

[2] St James Univ Hosp, Oncol, Leeds LS9 7TF, W Yorkshire, England

[3] MRC, Clin Trials Unit, London, England

[4] Mt Vernon Canc Ctr, Oncol, Northwood, Middx, England

[5] Christie Hosp, Med Oncol, Manchester, Lancs, England

[6] Royal Marsden Hosp, Oncol, Sutton, Surrey, England

[7] Christchurch Hosp, Oncol, Christchurch, New Zealand

[8] Hamilton Reg Canc Ctr, Med Oncol, Hamilton, ON L8V 1C3, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA10

引用

页码：S5 / S6

页数：2